Imatinib is a powerful
tyrosine kinase inhibitor that specifically targets BCR‑ABL, c‑KIT, and PDGFR
kinases, and is used in the treatment of
chronic myelogenous leukemia,
gastrointestinal stromal tumors, and other types of
cancers. However, the possible anticancer effects of
imatinib in
gastric cancer have not yet been explored. The present study evaluated the in vitro effects of
imatinib on
gastric cancer cells and determined the molecular mechanism underlying these effects. We determined that
imatinib induced mitochondria‑mediated apoptosis of
gastric cancer cells by involving endoplasmic reticulum (ER) stress‑associated activation of c‑Jun NH2‑terminal
kinase (JNK). We also found that
imatinib suppressed cell proliferation in a time‑ and dose‑dependent manner. Cell cycle analysis revealed that imatinib‑treated AGS cells were arrested in the G2/M phase of the cell cycle. Moreover, imatinib‑treated cells exhibited increased levels of phosphorylated JNK, and of the transcription factor C/EBP homologous
protein, an ER stress‑associated apoptotic molecule. Results of cell viability assays revealed that treatment with a combination of
imatinib and
chemotherapy agents
irinotecan or 5‑Fu synergistically inhibited cell growth, compared with treatment with any of these drugs alone. These data indicated that
imatinib exerted cytotoxic effects on
gastric cancer cells by inducing apoptosis mediated by
reactive oxygen species generation and ER stress‑associated JNK activation. Furthermore, we revealed that
imatinib induced the apoptosis of
gastric cancer cells by inhibiting platelet‑derived
growth factor receptor signaling. Collectively, our results strongly support the use of
imatinib in the treatment of treating
gastric cancer.